Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Shore on the Background and Outcomes of the EMBARK Trial in nmCSPC

February 15th 2024

Neal Shore, MD, FACS, discusses the phase 3 EMBARK study of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.

APEX-01 Looks to Add First PSMA-Directed ADC to Treatment Paradigm in mCRPC

February 13th 2024

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.

FDA Grants Fast Track Designation to BXCL701 for Small Cell Neuroendocrine Prostate Cancer

February 12th 2024

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

rPFS and cPFS May Act as Surrogate OS End Points in Phase 3 mHSPC Clinical Trials

February 9th 2024

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.

Apalutamide Plus ADT Improves PSA-PFS in High-Risk Biochemically Relapsed Prostate Cancer

February 9th 2024

Apalutamide plus androgen deprivation therapy improved prostate-specific antigen progression-free survival in castration-sensitive prostate cancer.

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

February 9th 2024

Summarizes the main points and benefits of multidisciplinary prostate cancer care.

Dr Takvorian on the Evolution of PARP Inhibitors in Prostate Cancer

February 8th 2024

Samuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.

HPN328 Shows Clinical Activity and Tolerability in Neuroendocrine Prostate Cancer

February 8th 2024

HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.

Dr Gong on the Current Treatment Armamentarium in mHSPC

February 7th 2024

Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Tinengotinib Shows Early Tolerability, Efficacy Signals in Heavily Pretreated mCRPC

February 5th 2024

Tinengotinib elicited responses with a manageable safety profile in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Clinical Case 4: Radiation Therapy

February 2nd 2024

Covers key factors in deciding on radiation treatment.

Clinical Case 3: Extensive Lymph Node Disease

February 2nd 2024

Discusses treatment options for advanced metastatic disease.

Dr Sharma on Questions Regarding the Optimal Use of Triplet Therapies in HSPC

February 2nd 2024

Janaki Neela Sharma, MD, discusses data with triplet therapies in patients with hormone-sensitive prostate cancer.

Clinical Case 2: Solitary Lymph Node

January 30th 2024

Looks at approaches for isolated lymph node involvement.

Clinical Case 1b: Elderly Patient Surgery

January 30th 2024

Examines the considerations for operating on older prostate cancer patients.

Dr. Gong on Addressing Unmet Needs Through Ongoing Research in Prostate Cancer

January 29th 2024

Jun Gong, MD, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer.

Dr Kaakour on the Rationale For Evaluating Genomic Testing Patterns in Prostate Cancer

January 26th 2024

Dalia Kaakour, MD, discusses real-world findings on genomic testing patterns in patients with prostate cancer.

Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC

January 25th 2024

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Real-World Findings Emphasize the Need for Early Genetic Testing in HRR-Mutated mCRPC

January 25th 2024

Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.

Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC

January 25th 2024

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.